What Is LPC70 (the Soy Compound) and Can It Actually Protect Your Brain From High-Salt Damage? What the New Research Shows

At a Glance: What LPC70 Did (and Did Not Do) in the 2026 Mouse Study

The table below summarises the key experimental outcomes reported across the two most recent LPC70 studies from the Fujita Health University group, giving a side-by-side picture of what changed with a high-salt diet (HSD) and what LPC70 reversed.

Outcome / Biomarker	Normal Diet (control)	High-Salt Diet (HSD) alone	HSD + LPC70
Systolic blood pressure	Baseline	Significantly elevated	Attenuated toward baseline
Object recognition memory	Intact	Impaired	Restored
Social interaction behaviour	Normal	Reduced	Improved
Locomotor activity / anxiety	Normal	Unchanged	Unchanged
Renal COX-2 expression	Baseline	Increased	Reduced
Renal EP3 (PGE2 receptor) expression	Baseline	Increased	Reduced
Prefrontal cortex DP1 (PGD2 receptor) expression	Baseline	Decreased	Restored
Prefrontal cortex DP2 expression	Baseline	Unchanged	Unchanged
Circulating arachidonic acid (AA)	Baseline	Decreased	Decreased (but AA-derived PGs increased)
PGE2 and PGD2 production	Baseline	Altered	Increased vs. HSD alone
Small intestine iNOS expression (2024 study)	Baseline	Increased	Suppressed
Tau hyperphosphorylation in prefrontal cortex (2024 study)	Baseline	Increased	Prevented

Sources: Kubota et al., Neurochemistry International 2026; Kubota et al., Neurochemistry International 2024.

LPC70 is a form of soy lysolecithin in which lysophosphatidylcholine (LPC) accounts for more than 70% of the total phospholipid content — a concentration that distinguishes it from ordinary soybean lecithin supplements found on pharmacy shelves. In a study published in Neurochemistry International, Volume 197 (July 2026), researchers at Fujita Health University in Japan found that mice supplemented with LPC70 while consuming a high-salt diet showed lower blood pressure, better object recognition memory, and improved social interaction compared with mice eating excess salt alone. The findings are preliminary — all data come from animal experiments — but they open a credible mechanistic window into how a food-grade soy ingredient might blunt two of the most damaging consequences of a high-salt diet: cardiovascular stress and cognitive decline.

What exactly is LPC70, and where does it come from?

LPC70 is a soy lysolecithin preparation in which lysophosphatidylcholine (LPC) constitutes more than 70% of the phospholipid fraction. Lysolecithin is a modified form of lecithin — a phospholipid found abundantly in soybeans — in which one of the two fatty acid chains has been removed, leaving a single fatty acid attached to the glycerol backbone. This structural difference makes lysolecithin more water-soluble than conventional lecithin and alters how it interacts with cell membranes and signalling pathways.

Ordinary soybean lecithin is one of the most widely consumed phospholipid supplements globally, used in food manufacturing as an emulsifier and sold as a dietary supplement. LPC70 is a more concentrated, standardised variant developed by Tsuji Oil Mills Co., Ltd., a Japanese company specialising in naturally derived food ingredients. It is not a pharmaceutical drug; it is positioned as a functional food ingredient, meaning it is intended to be incorporated into the diet rather than taken as a medicine.

The research into LPC70's health effects has been conducted through a collaborative programme between Tsuji Oil Mills and Fujita Health University, with partial funding from the Japan Society for the Promotion of Science and the Japan Science and Technology Agency. That industry involvement is worth noting when interpreting the results, though the studies were published in peer-reviewed journals and the mechanistic findings are internally consistent across multiple experiments.

Why does too much salt harm the brain, not just the heart?

Most people understand that high salt intake raises blood pressure by increasing fluid retention and vascular resistance. What is less widely appreciated is that excessive salt also appears to damage the brain through mechanisms that go beyond simple haemodynamic stress.

The 2026 Neurochemistry International paper notes that the World Health Organization recommends limiting daily salt consumption to under 5 grams, yet average global intake runs at approximately 10 grams per day — with particularly high consumption in Asian countries. That chronic excess sets off a cascade of peripheral and central nervous system changes.

In the gut, high salt intake increases expression of inducible nitric oxide synthase (iNOS) in the small intestine, promoting intestinal inflammation. The 2024 predecessor study from the same research group found that this intestinal inflammation was associated with tau hyperphosphorylation in the prefrontal cortex — a molecular change linked to the protein tangles seen in neurodegenerative disease.

In the kidneys, excess salt drives up production of prostaglandin E2 (PGE2) through elevated cyclooxygenase-2 (COX-2) activity and increases the sensitivity of blood vessels to PGE2's vasoconstrictive signals via the EP3 receptor. This contributes to sustained high blood pressure.

In the brain itself, high salt reduces expression of the PGD2 receptor DP1 in the prefrontal cortex — a region critical for working memory, social cognition, and executive function. DP1 is associated with anti-inflammatory, neuroprotective signalling. When its expression drops, the brain becomes more vulnerable to inflammatory damage. The other PGD2 receptor, DP2, which is associated with harmful neurotoxic signalling, remains unaffected by high salt — meaning the balance tips toward harm.

The behavioural consequences observed in mice on a high-salt diet were specific: impaired object recognition memory and reduced social interaction, but no change in general locomotor activity or anxiety-like behaviour. This selectivity suggests that high salt preferentially disrupts higher-order cognitive and social functions rather than causing global neurological impairment — a pattern that has relevance for understanding why some people with hypertension experience subtle cognitive changes before more overt neurological symptoms appear.

How does LPC70 actually work inside the body?

The 2026 study is the first to map LPC70's mechanism of action at the level of prostaglandin signalling pathways, and the picture that emerges is more detailed than a simple "anti-inflammatory compound" narrative.

Prostaglandins are lipid signalling molecules derived from arachidonic acid (AA) by the action of cyclooxygenase (COX) enzymes. They function as local hormones, exerting highly localised effects depending on which receptor subtypes are present in a given tissue. The same prostaglandin can produce opposite effects in different organs — PGE2, for instance, can dilate blood vessels in some contexts and constrict them in others, depending on which EP receptor it binds.

LPC70 appears to exploit this receptor specificity in two distinct organ systems simultaneously.

In the kidneys, the high-salt diet increased both COX-2 expression and EP3 receptor expression. EP3 is associated with vasoconstrictive, pro-hypertensive PGE2 signalling. LPC70 reduced both of these increases, suggesting it normalises the maladaptive prostaglandin signalling that contributes to salt-induced hypertension. The effect is suppressive in this organ — LPC70 dials down an overactive pathway.

In the prefrontal cortex, the dynamic is reversed. High salt had reduced DP1 expression — the neuroprotective PGD2 receptor — while leaving DP2 (the neurotoxic receptor) untouched. LPC70 restored DP1 expression without altering DP2. This is a selective, restorative effect rather than a blanket suppression of prostaglandin activity. By restoring DP1 without boosting DP2, LPC70 effectively shifts the brain's prostaglandin signalling balance back toward neuroprotection.

There is also a surprising finding at the level of arachidonic acid itself. Mice on a high-salt diet had lower levels of circulating AA — the raw material for prostaglandin production. Yet when LPC70 was added, levels of AA-derived prostaglandins (both PGE2 and PGD2) increased. The researchers interpret this as evidence that LPC70 enhances the body's efficiency in converting available AA into prostaglandins under high-salt conditions, rather than simply increasing the supply of AA. The compound appears to act as a metabolic driver of prostaglandin production when the system is under stress.

This organ-specific, receptor-selective, and metabolically efficient profile is what makes LPC70 mechanistically interesting. It is not acting like a COX inhibitor, which would broadly suppress prostaglandin production everywhere, including in protective pathways. Instead, it appears to fine-tune the system in a context-dependent way.

What did the earlier 2024 study find, and how does it connect?

The 2026 paper builds on a 2024 study by the same Fujita Health University group, also published in Neurochemistry International, which established LPC70's efficacy before the mechanism was understood.

In that earlier experiment, mice were given a 2% NaCl solution in their drinking water for 12 weeks — a different protocol from the 2026 study's 8% NaCl chow for 10 weeks, though both models reliably produce hypertension and cognitive impairment. The 2024 study found that LPC70 prevented both hypertension and impaired object recognition memory, and traced part of the mechanism to the gut-brain axis: LPC70 suppressed iNOS expression in the small intestine and prevented tau hyperphosphorylation in the prefrontal cortex.

Tau hyperphosphorylation is a molecular hallmark of Alzheimer's disease and other tauopathies. That a dietary high-salt protocol was sufficient to induce this change in mice — and that LPC70 could prevent it — is one of the more striking findings in this line of research, even if the clinical implications for humans remain entirely speculative at this stage.

Together, the two studies paint a picture of LPC70 acting through at least two distinct pathways: an intestinal anti-inflammatory pathway (identified in 2024) and a prostaglandin signalling pathway (characterised in 2026). Whether these pathways are independent or interconnected is not yet clear.

What are the study's limitations, and how seriously should these results be taken?

These findings are promising but far from conclusive for human health applications. Several limitations deserve explicit acknowledgement.

All data come from mouse models. Rodent models of hypertension and cognitive impairment do not always translate to human physiology, and the doses and durations used in mouse experiments rarely map cleanly onto human supplementation protocols. As ScienceDaily reported in its coverage of the study, "further clinical studies are needed to determine whether the same benefits occur in humans."

The high-salt protocols are also extreme. An 8% NaCl chow is a very high salt concentration — far above what even heavy salt consumers typically eat. This makes the model useful for studying mechanisms but less representative of real-world dietary patterns.

Industry funding creates a potential conflict of interest. Tsuji Oil Mills Co., Ltd. — the company that produces LPC70 — provided funding for the research and several of its employees are co-authors on the paper. The researchers and journal have disclosed this, and the mechanistic findings are detailed and internally consistent, but independent replication would strengthen confidence in the results.

No dose-response data for humans exist. The studies do not establish what dose of LPC70 a human would need to consume to achieve similar effects, or whether the compound is safe at those doses over long periods. Behavioural tests in mice are also imperfect proxies for human cognition: object recognition memory and social interaction tests measure specific, well-validated behaviours, but they are not direct equivalents of the complex cognitive functions affected by hypertension in humans.

None of these limitations invalidate the research. They simply mean that LPC70 is currently a scientifically interesting candidate compound, not a proven intervention. Prof. Mouri's own conclusion frames it accurately: the study "lays the groundwork for future clinical research and dietary interventions," not a ready-to-use treatment.

How does LPC70 compare to other dietary approaches for salt-related health risks?

LPC70 is not the only dietary strategy being investigated for mitigating high-salt damage. The broader space of nutritional approaches to hypertension and cognitive protection includes several well-studied options, each with different evidence bases and mechanisms.

Omega-3 fatty acids — particularly DHA and EPA from marine or algae sources — have established anti-inflammatory and blood-pressure-modulating effects, with a substantially larger human clinical trial base than LPC70. Berberine has shown promise for blood sugar and cardiovascular risk in human studies. Plant-based compounds like Arjuna have traditional use and some clinical data for heart health.

What makes LPC70 distinct is its proposed mechanism: rather than broadly reducing inflammation or blood pressure through a single pathway, it appears to modulate prostaglandin receptor expression in an organ-specific way. If this mechanism holds in humans, it could offer a more targeted approach than general anti-inflammatory supplementation. But the human data simply do not exist yet.

For people currently managing high blood pressure or concerned about cognitive health, the most evidence-backed dietary interventions remain sodium restriction itself, the DASH diet, increased potassium intake, and regular aerobic exercise. LPC70 is not a substitute for any of these; at best, it might eventually become a complementary functional food ingredient for populations with high dietary salt exposure.

Could LPC70 become a functional food ingredient, and what would that look like?

The framing of LPC70 as a "functional food ingredient" rather than a pharmaceutical is deliberate and significant. Functional food ingredients are food components that provide health benefits beyond basic nutrition, typically incorporated into everyday foods or sold as dietary supplements rather than prescribed as medicines.

Soybean lecithin is already one of the most widely used food additives in the world — it appears in chocolate, baked goods, infant formula, and countless processed foods as an emulsifier. LPC70, as a more concentrated and standardised lysolecithin fraction, could theoretically be incorporated into similar food products or sold as a standalone supplement, subject to regulatory approval in each market.

Tsuji Oil Mills is the commercial developer of LPC70, and the company's involvement in the research suggests an eventual product pathway is being considered. Regulatory approval for health claims — particularly cognitive health claims — requires human clinical trial data demonstrating efficacy and safety, and that data does not yet exist for LPC70.

The compound's safety profile in mice appears acceptable based on the published studies, which reported no adverse behavioural effects from LPC70 supplementation in normal or high-salt-diet animals. Long-term safety in humans, interactions with medications (particularly anticoagulants, given that phospholipids affect platelet function), and appropriate dosing all remain open questions.

What should someone with high blood pressure or cognitive concerns take away from this research?

The research on LPC70 is genuinely exciting from a mechanistic science perspective. The finding that a soy-derived food compound can selectively restore neuroprotective prostaglandin receptor expression in the prefrontal cortex while simultaneously suppressing pro-hypertensive signalling in the kidneys — through what appears to be a coordinated, organ-specific response — is the kind of result that justifies further investigation.

The gap between "works in mice on an extreme high-salt diet" and "should be taken as a supplement by humans" is large, however, and responsible science communication requires stating that clearly. There are no human trials. There is no established human dose. There is no regulatory approval for LPC70 health claims in any major market as of October 2026.

What this research does offer is a plausible biological rationale for why dietary phospholipid composition might matter for both cardiovascular and brain health — and a specific compound worth watching as clinical research develops. People concerned about blood pressure or cognitive decline related to high salt intake should focus on the interventions with established human evidence: reducing sodium intake, increasing dietary potassium, maintaining a heart-healthy diet, and consulting a physician about any supplementation.

If the prostaglandin signalling mechanism identified in these mouse studies replicates in human tissue, and if clinical trials confirm even a fraction of the blood pressure and cognitive benefits seen in rodents, LPC70 could eventually become a meaningful addition to the functional food toolkit for healthy ageing. That is a meaningful "if" — but not an implausible one.